BioMarin Scores Patent Board Win; Sarepta To Appeal
This article was originally published in Scrip
Shares of BioMarin Pharmaceutical Inc. leaped more than 13% on Sept. 30 after the firm scored a win at the Patent Trial and Appeal Board (PTAB) of the U.S. Patent & Trademark Office (US PTO) in a patent interference dispute with Sarepta Therapeutics Inc. involving methods of use claims for the firms' respective experimental Duchenne muscular dystrophy (DMD) drugs drisapersen and eteplirsen.
You may also be interested in...
Morningstar expects 229% revenue growth during the 2015-2020 period for BioMarin, far stronger than larger competitors. Virology powerhouse Gilead is the only one of the 20 largest biopharmas expected to face a decline in revenue over the period.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.